RU2455311C2 - Производные полимиксина и их применения - Google Patents
Производные полимиксина и их применения Download PDFInfo
- Publication number
- RU2455311C2 RU2455311C2 RU2009107857/04A RU2009107857A RU2455311C2 RU 2455311 C2 RU2455311 C2 RU 2455311C2 RU 2009107857/04 A RU2009107857/04 A RU 2009107857/04A RU 2009107857 A RU2009107857 A RU 2009107857A RU 2455311 C2 RU2455311 C2 RU 2455311C2
- Authority
- RU
- Russia
- Prior art keywords
- derivative
- seq
- gram
- polymyxin
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract 28
- 241000894006 Bacteria Species 0.000 claims abstract 26
- 239000003242 anti bacterial agent Substances 0.000 claims abstract 16
- 125000000539 amino acid group Chemical group 0.000 claims abstract 8
- 230000001235 sensitizing effect Effects 0.000 claims abstract 6
- 208000015181 infectious disease Diseases 0.000 claims abstract 5
- 230000007935 neutral effect Effects 0.000 claims abstract 4
- 210000002966 serum Anatomy 0.000 claims abstract 4
- 230000000295 complement effect Effects 0.000 claims abstract 3
- 230000009979 protective mechanism Effects 0.000 claims abstract 3
- 206010029155 Nephropathy toxic Diseases 0.000 claims abstract 2
- 229940088710 antibiotic agent Drugs 0.000 claims abstract 2
- 125000002091 cationic group Chemical group 0.000 claims abstract 2
- 230000007694 nephrotoxicity Effects 0.000 claims abstract 2
- 231100000417 nephrotoxicity Toxicity 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 108010040201 Polymyxins Proteins 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 13
- 241000588626 Acinetobacter baumannii Species 0.000 claims 6
- 241000588919 Citrobacter freundii Species 0.000 claims 6
- 241000588697 Enterobacter cloacae Species 0.000 claims 6
- 241000588724 Escherichia coli Species 0.000 claims 6
- 241000588749 Klebsiella oxytoca Species 0.000 claims 6
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 6
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- HEDADCOWECPKFY-UHFFFAOYSA-N octapeptin Chemical compound CCC(C)CCCCC(O)CC(=O)NC(CCN)C(=O)NC1CCNC(=O)C(CC(C)C)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O HEDADCOWECPKFY-UHFFFAOYSA-N 0.000 claims 5
- 108010093294 octapeptin antibiotics Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 4
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- 230000000844 anti-bacterial effect Effects 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 229960004675 fusidic acid Drugs 0.000 claims 4
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims 4
- 229960003128 mupirocin Drugs 0.000 claims 4
- 229930187697 mupirocin Natural products 0.000 claims 4
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- -1 6-methylheptanoyl Chemical group 0.000 claims 3
- 108010034396 Streptogramins Proteins 0.000 claims 3
- 230000004888 barrier function Effects 0.000 claims 3
- 229940124307 fluoroquinolone Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 229940041153 polymyxins Drugs 0.000 claims 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 3
- KOFBVFFPLADGGO-DUSUDKPKSA-N (3r,4s,5r,6r)-6-[(1r,2r)-1-amino-2-hydroxypropyl]oxane-2,3,4,5-tetrol Chemical compound C[C@@H](O)[C@@H](N)[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O KOFBVFFPLADGGO-DUSUDKPKSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 229930189077 Rifamycin Natural products 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 2
- 229960004099 azithromycin Drugs 0.000 claims 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 2
- 229960002626 clarithromycin Drugs 0.000 claims 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 2
- 229960002227 clindamycin Drugs 0.000 claims 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims 2
- 229960003276 erythromycin Drugs 0.000 claims 2
- 229940014144 folate Drugs 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- 229960001225 rifampicin Drugs 0.000 claims 2
- 229960003292 rifamycin Drugs 0.000 claims 2
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 2
- 229960001082 trimethoprim Drugs 0.000 claims 2
- 239000002132 β-lactam antibiotic Substances 0.000 claims 2
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 2
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 150000002190 fatty acyls Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 231100001231 less toxic Toxicity 0.000 claims 1
- 229960003907 linezolid Drugs 0.000 claims 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- 229960005266 polymyxin b Drugs 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 108010071077 quinupristin-dalfopristin Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- C07K7/62—Polymyxins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83742606P | 2006-08-11 | 2006-08-11 | |
| DKPA200601055 | 2006-08-11 | ||
| US60/837,426 | 2006-08-11 | ||
| DKPA200601055 | 2006-08-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009107857A RU2009107857A (ru) | 2010-09-20 |
| RU2455311C2 true RU2455311C2 (ru) | 2012-07-10 |
Family
ID=39032653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009107857/04A RU2455311C2 (ru) | 2006-08-11 | 2007-08-10 | Производные полимиксина и их применения |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP2057185B1 (enExample) |
| JP (1) | JP5226685B2 (enExample) |
| KR (2) | KR20150008198A (enExample) |
| CN (2) | CN101501063B (enExample) |
| AU (1) | AU2007283514B2 (enExample) |
| BR (1) | BRPI0715095B8 (enExample) |
| CA (1) | CA2694289C (enExample) |
| CY (1) | CY1117848T1 (enExample) |
| DK (1) | DK2057185T3 (enExample) |
| ES (1) | ES2575521T3 (enExample) |
| HR (1) | HRP20160552T1 (enExample) |
| HU (1) | HUE028271T2 (enExample) |
| IL (2) | IL196693B (enExample) |
| MX (1) | MX2009001398A (enExample) |
| NO (1) | NO341982B1 (enExample) |
| NZ (1) | NZ575421A (enExample) |
| PL (1) | PL2057185T3 (enExample) |
| PT (1) | PT2057185E (enExample) |
| RU (1) | RU2455311C2 (enExample) |
| SI (1) | SI2057185T1 (enExample) |
| WO (1) | WO2008017734A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2492179C2 (ru) * | 2008-02-08 | 2013-09-10 | Нозерн Антибиотикс Ой | Производные полимиксина с короткоцепочечным жирнокислотным хвостом и их применение |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060004185A1 (en) | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| US8343912B2 (en) | 2008-12-23 | 2013-01-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2012051663A1 (en) * | 2010-10-21 | 2012-04-26 | Monash University | Antimicrobial compounds |
| EP2780357A1 (en) | 2011-11-18 | 2014-09-24 | Novacta Biosystems Limited | Polymyxin derivatives |
| EP2999711B1 (en) * | 2013-05-22 | 2022-06-29 | Spero Therapeutics, Inc. | Polymyxin derivatives and their use in combination therapy together with different antibiotics |
| KR20160135739A (ko) * | 2014-03-11 | 2016-11-28 | 뉴 파마 라이센스 홀딩스 리미티드 | 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도 |
| KR101664106B1 (ko) | 2014-09-11 | 2016-10-10 | 한국화학연구원 | 폴리믹신 b 화합물을 포함하는 심혈관 질환의 예방 및 치료용 약학적 조성물 |
| WO2016083531A1 (en) | 2014-11-26 | 2016-06-02 | New Pharma Licence Holdings Limited | Compounds |
| JP6896628B2 (ja) | 2014-12-16 | 2021-06-30 | シャンハイ ミクウルク ファーマシューティカル シーオー．エルティーディー | 細菌感染症の治療のための抗微生物性ポリミキシン |
| JP6629327B2 (ja) * | 2014-12-18 | 2020-01-15 | ヘルパービー セラピューティクス リミテッドＨｅｌｐｅｒｂｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 微生物感染の予防または治療で使用される組み合わせ |
| FI126143B (en) * | 2015-01-15 | 2016-07-15 | Northern Antibiotics Oy | Polymyxine derivative and its uses |
| US9763996B2 (en) | 2015-01-16 | 2017-09-19 | Northern Antibiotics, Ltd. | Polymyxin derivative and uses thereof |
| CN104672307B (zh) * | 2015-03-23 | 2017-09-29 | 吉林大学 | 一种提高阳离子短肽抗菌性和稳定性的方法 |
| EP3072956A1 (en) * | 2015-03-25 | 2016-09-28 | Université de Fribourg | Selective culture medium for polymyxin-resistant, gram-negative bacteria |
| FR3036406B1 (fr) | 2015-05-20 | 2019-07-19 | Biomerieux | Identification des bacteries resistantes aux carbapenemes par impermeabilite membranaire |
| EP3374027B1 (en) * | 2015-11-12 | 2021-06-23 | The Trustees of Columbia University in the City of New York | Rational drug design targeting resistant gram-negative bacterial infections to polymyxin-class antibiotics |
| WO2017189868A1 (en) * | 2016-04-27 | 2017-11-02 | Spero Opco | Serine replacement polymyxin analogues useful as antibiotic potentiators |
| WO2017189866A1 (en) * | 2016-04-27 | 2017-11-02 | Spero Opco | Polymyxin analogs useful as antibiotic potentiators |
| GB201703898D0 (en) | 2017-03-10 | 2017-04-26 | Helperby Therapeautics Ltd | Method |
| GB201704620D0 (en) | 2017-03-23 | 2017-05-10 | Helperby Therapeautics Ltd | Combinations |
| AU2018359018B2 (en) * | 2017-11-02 | 2022-11-24 | The University Of Queensland | Peptide antibiotics |
| EP3560489A1 (en) * | 2018-04-27 | 2019-10-30 | European Molecular Biology Laboratory | Pharmaceutical compositions for prevention and/or treatment of infections and antibacterial-induced dysfunctions |
| KR20210054500A (ko) | 2018-06-25 | 2021-05-13 | 스페로 테라퓨틱스, 인코퍼레이티드 | 화합물 |
| CN112739710B (zh) * | 2018-07-19 | 2024-08-27 | 东北大学 | 具有抗菌特性的化合物 |
| CN110179967A (zh) * | 2019-05-28 | 2019-08-30 | 中国医药集团总公司四川抗菌素工业研究所 | 多粘菌素母核和一种抗生素的组合物及其应用 |
| IT201900025414A1 (it) * | 2019-12-23 | 2021-06-23 | Univ Bologna Alma Mater Studiorum | Composto per il trattamento della sindrome emolitico uremica |
| CN115298198A (zh) | 2020-01-21 | 2022-11-04 | 上海盟科药业股份有限公司 | 用于肾相关癌症靶向治疗的新型化合物和组合物 |
| CN118028501B (zh) * | 2022-08-30 | 2024-08-02 | 四川大学华西医院 | 一类phoQ基因突变体、应用及其验证方法 |
| WO2024123712A1 (en) * | 2022-12-04 | 2024-06-13 | Genentech, Inc. | Analysis of candidate cytotoxic compositions |
| CN120399010B (zh) * | 2025-07-01 | 2025-09-12 | 杭州肽佳生物科技有限公司 | 抗生素多粘菌素的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4510132A (en) * | 1982-10-06 | 1985-04-09 | Martti Vaara | Compounds for use in antibacterial therapy |
| WO2006083317A9 (en) * | 2004-07-01 | 2007-03-01 | Biosource Pharm Inc | Peptide antibiotics and methods for making same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3450687A (en) | 1966-02-24 | 1969-06-17 | Pfizer & Co C | Lower alkanoyl esters of polymyxin antibiotics |
| JPS4915537B1 (enExample) | 1970-03-25 | 1974-04-16 | ||
| BE754411A (fr) | 1969-08-05 | 1971-02-04 | Rhone Poulenc Sa | Cyclopeptides derives des polymyxines et leur |
| IL155976A0 (en) * | 2000-11-20 | 2003-12-23 | Daiichi Seiyaku Co | Dehalogeno compounds |
| CA2444637A1 (en) | 2001-01-16 | 2002-07-18 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Hybrid peptides for treatment of bacteremia and septicemia |
| DE60217060T2 (de) * | 2002-03-01 | 2007-06-21 | Chiesi Farmaceutici S.P.A. | Pharmazeutische Zusammensetzungen, die Lungensurfactants und ein Polymyxin umfassen und verbesserte Oberflächenspannung-senkende Eigenschaften haben |
-
2007
- 2007-08-10 EP EP07803704.1A patent/EP2057185B1/en active Active
- 2007-08-10 ES ES07803704.1T patent/ES2575521T3/es active Active
- 2007-08-10 HU HUE07803704A patent/HUE028271T2/en unknown
- 2007-08-10 AU AU2007283514A patent/AU2007283514B2/en not_active Ceased
- 2007-08-10 MX MX2009001398A patent/MX2009001398A/es active IP Right Grant
- 2007-08-10 HR HRP20160552TT patent/HRP20160552T1/hr unknown
- 2007-08-10 WO PCT/FI2007/050441 patent/WO2008017734A1/en not_active Ceased
- 2007-08-10 BR BRPI0715095A patent/BRPI0715095B8/pt not_active IP Right Cessation
- 2007-08-10 CA CA 2694289 patent/CA2694289C/en active Active
- 2007-08-10 RU RU2009107857/04A patent/RU2455311C2/ru active
- 2007-08-10 NZ NZ575421A patent/NZ575421A/en not_active IP Right Cessation
- 2007-08-10 CN CN200780029855.5A patent/CN101501063B/zh not_active Expired - Fee Related
- 2007-08-10 PL PL07803704.1T patent/PL2057185T3/pl unknown
- 2007-08-10 KR KR1020147036680A patent/KR20150008198A/ko not_active Ceased
- 2007-08-10 EP EP16168287.7A patent/EP3078672A1/en not_active Withdrawn
- 2007-08-10 KR KR1020097004841A patent/KR101502453B1/ko not_active Expired - Fee Related
- 2007-08-10 CN CN201310011979.8A patent/CN103059106B/zh not_active Expired - Fee Related
- 2007-08-10 JP JP2009523312A patent/JP5226685B2/ja not_active Expired - Fee Related
- 2007-08-10 PT PT07803704T patent/PT2057185E/pt unknown
- 2007-08-10 DK DK07803704.1T patent/DK2057185T3/en active
- 2007-08-10 SI SI200731783A patent/SI2057185T1/sl unknown
-
2009
- 2009-01-22 IL IL196693A patent/IL196693B/en active IP Right Grant
- 2009-02-12 NO NO20090674A patent/NO341982B1/no unknown
-
2012
- 2012-06-07 IL IL220270A patent/IL220270A0/en unknown
-
2016
- 2016-06-09 CY CY20161100502T patent/CY1117848T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4510132A (en) * | 1982-10-06 | 1985-04-09 | Martti Vaara | Compounds for use in antibacterial therapy |
| WO2006083317A9 (en) * | 2004-07-01 | 2007-03-01 | Biosource Pharm Inc | Peptide antibiotics and methods for making same |
Non-Patent Citations (1)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2492179C2 (ru) * | 2008-02-08 | 2013-09-10 | Нозерн Антибиотикс Ой | Производные полимиксина с короткоцепочечным жирнокислотным хвостом и их применение |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2455311C2 (ru) | Производные полимиксина и их применения | |
| JP6114275B2 (ja) | 窒素含有化合物及びその使用 | |
| JP5977344B2 (ja) | ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル | |
| JP6085829B2 (ja) | ピリミジンジャイレースおよびトポイソメラーゼｉｖ阻害剤 | |
| TWI595002B (zh) | （Ｒ）－２－（５－（２－（３－乙基脲基）－６－氟－７－（四氫呋喃－２－基）－１Ｈ－苯并［ｄ］咪唑－５－基）嘧啶－２－基）丙烷－２－基磷酸二氫鹽之固體形式及其鹽 | |
| US20040077533A1 (en) | Methods and compositions for treating bacterial infections and diseases associated therewith | |
| JP6411482B2 (ja) | 窒素含有化合物およびその使用 | |
| JP2017521432A (ja) | Ｎ−（疎水性置換）バンコサミニル［Ψ［Ｃ（＝ＮＨ）ＮＨ］Ｔｐｇ４］バンコマイシン及び［Ψ［ＣＨ２ＮＨ］Ｔｐｇ４］バンコマイシン | |
| CA2827578A1 (en) | Use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment | |
| AU2015339039B2 (en) | Synergistic compositions for treating microbial infections | |
| EP3265130A1 (en) | Antibacterial sideromycins | |
| RU2008102912A (ru) | Сочетание ингибиторов бетта-лактазмы бициклического 6-алкилиденпенема с бетта-лактанным антибиотиком: антибиотик широкого спектра | |
| SA515360628B1 (ar) | مركبات مضادة للبكتيريا | |
| CN116515102B (zh) | 星型β-抗菌糖肽、其制备方法及应用 | |
| CN102838661A (zh) | 万古霉素或去甲万古霉素类似物及其药用用途 | |
| WO2024191690A1 (en) | Vancomycin derivatives with siderophore modification as novel repurposed antibiotics to combat gram-negative bacterial infection | |
| WO2016125193A1 (en) | Glycopeptides conjugates and uses thereof | |
| JP2015105267A (ja) | 併用抗メチシリン耐性黄色ブドウ球菌薬、及びβラクタム系抗生物質の抗菌活性増強剤 | |
| Lancini et al. | Activities of the Antibiotics in Relation to Their Structures | |
| KR20160072152A (ko) | 질소 함유 화합물 및 이들의 용도 | |
| FR2941956A1 (fr) | NOUVELLES MOLECULES HYBRIDES VANCOMYCINE-AMINOQUINOLEINE DENOMMEES "VANCOMYQUINESr", LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
| HK1190150B (en) | Pyrimidine gyrase and topoisomerase iv inhibitors |